

"CMR International 2007 Pharmaceutical R&D Factbook"

Thomson, 2007, 70 pages, £1,100

Review by Norman M. Goldfarb

"CMR International 2007 Pharmaceutical R&D Factbook" presents the most important results from CMR performance benchmarking programs in 49 charts in nine chapters:

- Overview
- New Launches
- R&D Expenditure
- The Development Pipeline
- Success Rates
- Cycle Times
- Regional Comparisons
- Therapeutic Areas
- R&D Functions

For the interpretation-challenged, the implications of each chart are summarized. For a delightful change from most data in the industry, descriptions of methodology, definitions and data sources provide assurance that the charts mean what they claim to mean.

A few of the many fascinating findings include:

- In 2005, for the first time, the countries Canada, France, Germany, Italy, Japan, Spain, UK and USA accounted for less than 50% of subject enrollment in clinical trials.
- From 2002 to 2006, the pipeline of drugs in Phases I and II have grown by over 45%, while the pipeline of drugs in Phase III has grown by only 19%.
- The success rate of biotech-derived drugs entering Phase I is 80% higher than the success rate of small molecules.
- The success rate of anti-infective drugs entering Phase I is about double the rate of cardiovascular, anti-cancer and nervous system drugs.
- Only 20% of drugs entering Phase II reach the market.
- In 2006, 70% of R&D expenditure was devoted to new products (vs. line extensions, combination products, and "other").
- Global pharmaceutical sales are growing by 11% per year, while R&D expenditures are growing by only 6% per year.

The book is available at http://scientific.thomson.com/products/cmr_factbook/

Reviewer

Norman M. Goldfarb is Managing Director of First Clinical Research LLC, a provider of clinical research best practices information, consulting and training services. Contact him at 1.650.465.0119 or ngoldfarb@firstclinical.com.